株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界の細胞診断市場の考察、機会分析、市場シェア、予測

Global Tissue Diagnostics Market Insights, Opportunity, Analysis, Market Shares And Forecast 2016 - 2022

発行 Occams Business Research & Consulting Pvt. Ltd. 商品コード 363174
出版日 ページ情報 英文 140 Pages
納期: お問合せ
価格
本日の銀行送金レート: 1USD=113.97円で換算しております。
Back to Top
世界の細胞診断市場の考察、機会分析、市場シェア、予測 Global Tissue Diagnostics Market Insights, Opportunity, Analysis, Market Shares And Forecast 2016 - 2022
出版日: 2016年07月11日 ページ情報: 英文 140 Pages
概要

世界の細胞診断市場は、2022年までに48億1190万米ドルまで拡大すると見られています。市場は、2016年〜2022年のCAGR (複合年間成長率) で、8.6%の成長が予測されています。

当レポートでは、世界の細胞診断市場について調査分析し、市場概要、市場決定要因、部門別分析、地域別分析、企業プロファイルなど、体系的な情報を提供しています。

第1章 イントロダクション

第2章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
  • パラメーター分析
  • 主な市場考察
  • 競合情報
  • バリューチェーン分析
  • 主な購入基準
  • 戦略的提言
  • 戦略的結論

第3章 市場決定要因

  • 市場促進要因
  • 市場抑制要因
  • 市場の機会
  • 市場の課題

第4章 部門別分析

  • 親市場
  • サブセグメント市場
  • 代替市場

第5章 市場区分

  • 技術別
  • 疾患別
  • 製品別
  • エンドユーザー別

第6章 競合情勢

  • 市場シェア
  • 戦略

第7章 地域別分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • フランス
    • ドイツ
    • スペイン
    • イタリア
    • その他
  • アジア太平洋地域
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • その他
  • その他の地域

第8章 企業プロファイル

  • ROCHE
  • ABBOTT LABORATORIES, INC.
  • AGILENT TECHNOLOGIES
  • BIOGENEX LABORATORIES
  • BIO SB.
  • CELL SIGNALLING TECHNOLOGY, INC.
  • QIAGEN
  • BECTON DICKINSON & COMPANY
  • ALERE
  • DIAGENIC
  • MEDTRONIC INC
  • STRYKER
  • BIOMERIUX
  • PROMETHEUS LABORATORIES
  • DANAHER CORPORATION
目次
Product Code: HBI-1291015

The global tissue diagnostics market is expected to reach $4811.9 million by 2022 growing at 8.6% CAGR during 2016-2022. In regional outlook, market is divided into North America, Europe, Asia Pacific and rest of the world. North America dominates the global tissue diagnostics market, which accounts for around 40.7% of the global market share. The major reason boosting the North American region upward is the rising patient's awareness level, presence of technologically advanced products, and the rising healthcare expenditure. The United States and Canada are the major countries in North American region that boost the market growth. Asia Pacific is the fastest growing global tissue diagnostics market, due to rapid improvement in healthcare infrastructure, presence of sophisticated healthcare facilities in the developed markets of Australia and Japan. Asia Pacific is one of the most profitable and revenue generating market for major market players in the forecast period. China, Japan, South Korea and Australia are the major countries in Asia Pacific region. Europe is showing positive growth due to rising prevalence of cancer in this region, favorable government policies related to tissue diagnostics and increasing geriatric population. Rest of the world is showing positive growth rate for the global tissue diagnostics market in the forecast period. Brazil and Middle East is the major countries in the Rest of the world region.

Global tissue diagnostics market is segmented on the basis of technology, disease, products, end users and regional outlook. In technology segment, market is divided into immunohistochemistry, in situ hybridization, digital pathology and workflow management, magneto encephalograph and special staining. In disease segment, market is divided into breast cancer, gastric cancer, lymphoma, prostate cancer, non-small cell lung carcinoma and other disease. In product segment, market is divided into instrument and consumables. In end user segment, market is divided into hospitals, pharmaceuticals, research laboratories, contract research organization and others.

Global tissue diagnostics market is rising rapidly and is demanding for effective tissue diagnostic procedures majorly due to increasing prevalence of chronic diseases, such as liver cancer, brain cancer, lung cancer, colorectal, breast cancer, cervical cancers, cardiovascular disorders, malaria, and diabetes and many more. Apart from this, the increased use of biomarkers for disease diagnosis has a positive impact on the market for global tissue diagnostics in the forecast period. Biomarkers help to evaluate the physiological, pharmacological and disease processes, and are broadly used for various clinical studies in the area of genomics, proteomics, metabolomics and transcriptomics. The ability of biomarkers to aid in the purpose of disease prognosis, elucidation of pathways is majorly affected by the disease and identification of individuals which is likely to respond to specific therapeutic interventions, which will result in its better utilization during the forecast period.

Some of the major market players are Danaher corporation, Medtronic Inc., GE healthcare, Ventana medical Systems, Thermo fisher scientific, Asuragen Inc., Johnson & Johnson, Span Diagnostics, Cadwell laboratories Inc., veridex, Xcyton diagnostic, Sekisui diagnostic, etc. Acquisition, mergers and expansions are the key strategies adopted by the market players to sustain in the market.

Table of Contents

1. INTRODUCTION

  • 1.1. EXECUTIVE SUMMARY
  • 1.2. ESTIMATION METHODOLOGY

2. MARKET OVERVIEW

  • 2.1. MARKET DEFINITION AND SCOPE
  • 2.2. KEY FINDINGS
  • 2.3. PARAMETRIC ANALYSIS
    • 2.3.1. PREVALENCE & INCIDENCE RATE OF CANCER
    • 2.3.2. PREVALENCE & INCIDENCE RATE OF NEURO-DEGENERATIVE DISEASES
    • 2.3.3. HOSPITAL AND RESEARCH CENTER ACROSS GEOGRAPHIES
    • 2.3.4. RISE IN DISPOSABLE INCOMES IN EMERGING ECONOMIES
    • 2.3.5. HEALTHCARE EXPENDITURE ACROSS GEOGRAPHIES
  • 2.4. KEY MARKET INSIGHTS
    • 2.4.1. TOP 3 EMERGING COUNTRIES
    • 2.4.2. TOP 3 REVENUE GENERATING SEGMENTS
    • 2.4.3. TOP GROWING MARKETS AND EMERGING TRENDS
    • 2.4.4. EP 2764124 A4: DIAGNOSTIC ASSAY FOR TISSUE TRANSPLANTATION PATENT ANALYSIS STATUS
      • 2.4.4.1. EP 2764091 A4: DIAGNOSTIC METHOD FOR CONNECTIVE TISSUE ANT ITS APPLICATION
      • 2.4.4.2. EP 2764091 A4: DIAGNOSTIC METHOD FOR CONNECTIVE TISSUE ANT ITS APPLICATION
      • 2.4.4.3. EP 2761268 A4: ULTRA-RAPID DIAGNOSTIC TISSUE PREPARATION AS AN ALTERNATIVE TO FROZEN SECTION
    • 2.4.5. R&D SCENARIO IN BRAIN MONITORING MARKET
      • 2.4.5.1. R&D IN ADVANCE TISSUE DIAGNOSTICS
      • 2.4.5.2. R&D IN IN-VITRO DIAGNOSTICS
      • 2.4.5.3. R&D IN CANCER THERAPEUTICS
  • 2.5. COMPETITIVE INTELLIGENCE
    • 2.5.1. MARKET SHARE ANALYSIS
    • 2.5.2. TOP WINNING STRATEGIES
    • 2.5.3. CASE STUDIES: TOP COMPETITIVE MOVES
  • 2.6. VALUE CHAIN ANALYSIS
  • 2.7. KEY BUYING CRITERIA
  • 2.8. STRATEGIC RECOMMENDATION
  • 2.9. STRATEGIC CONCLUSIONS

3. MARKET DETERMINANTS

  • 3.1. MARKET DRIVERS
    • 3.1.1. GLOBAL RISE IN IN-VITRO DIAGNOSTICS ENABLES TISSUE DIAGNOSTIC MARKET TO GROW FAST
    • 3.1.2. GLOBAL RISE IN CANCER DIAGNOSTICS AND TREATMENT
    • 3.1.3. GLOBAL RISE IN ADOPTION OF DIAGNOSTICS GIVING RISE TO GLOBAL TISSUE DIAGNOSTIC MARKET
    • 3.1.4. TECHNOLOGICAL ADVANCEMENT ENABLES TO EXPAND GLOBAL TISSUE DIAGNOSTIC MARKET
    • 3.1.5. INNOVATION GIVING RISE TO GROWTH OF GLOBAL TISSUE DIAGNOSTIC MARKET
    • 3.1.6. GLOBAL INCREASE IN HEALTHCARE EXPENDITURE
    • 3.1.7. RISE IN ADOPTION OF PERSONALIZED MEDICINES IS DRIVING THE GLOBAL TISSUE DIAGNOSTIC MARKET
    • 3.1.8. FUNDING FROM GOVERNMENT AND PRIVATE PLAYERS TO BOOST GLOBAL TISSUE DIAGNOSTIC MARKET
  • 3.2. MARKET RESTRAINTS
    • 3.2.1. HIGH COST OF TISSUE DIAGNOSTICS AFFECTS GLOBAL TISSUE DIAGNOSTIC MARKET
    • 3.2.2. REIMBURSEMENT ISSUES CREATES HURDLES IN THE GROWTH OF GLOBAL TISSUE DIAGNOSTIC MARKET
  • 3.3. MARKET CHALLENGES
    • 3.3.1. CREATING AWARENESS FOR GLOBAL TISSUE DIAGNOSTIC MARKET
    • 3.3.2. GLOBAL ECONOMIC SLOWDOWN MAY AFFECT THE GLOBAL BRAIN MONITORING MARKET
    • 3.3.3. STRINGENT GOVERNMENT REGULATIONS AND POLICIES MAY AFFECT GLOBAL TISSUE DIAGNOSTIC MARKET
  • 3.4. MARKET OPPORTUNITIES
    • 3.4.1. FDA APPROVALS GIVING RISE TO SIGNIFICANT SCOPE IN GLOBAL TISSUE DIAGNOSTIC MARKET
    • 3.4.2. ADVANCEMENTS IN DIAGNOSTICS CREATING SCOPE FOR GLOBAL TISSUE DIAGNOSTIC MARKET
    • 3.4.3. RISING CANCER DISEASES CREATES DEMAND FOR GLOBAL TISSUE DIAGNOSTIC MARKET

4. SECTOR ANALYSIS

  • 4.1. PARENT MARKET
  • 4.2. SUB-SEGMENT MARKET
  • 4.3. ALTERNATIVE MARKET

5. MARKET SEGMENTATION

  • 5.1. GLOBAL TISSUE DIAGNOSTIC MARKET BY TECHNOLOGY, 2014-2022,($ MILLIONS)
    • 5.1.1. GLOBAL IMMUNOHISTOCHEMISTRY MARKET BY PRODUCT, 2014-2022,($ MILLIONS)
    • 5.1.2. GLOBAL IN SITU HYBRIDIZATION MARKET, 2014-2022,($ MILLIONS)
    • 5.1.3. GLOBAL DIGITAL PATHOLOGY AND WORKFLOW MANAGEMENT MARKET, 2014-2022,($ MILLIONS)
    • 5.1.4. GLOBAL MAGNETOENCEPHALOGRAPH MARKET, 2014-2022,($ MILLIONS)
    • 5.1.5. GLOBAL SPECIAL STAINING MARKET, 2014-2022,($ MILLIONS)
  • 5.2. GLOBAL TISSUE DIAGNOSTIC MARKET BY DISEASE, 2014-2022,($ MILLIONS)
    • 5.2.1. GLOBAL BREAST CANCER MARKET, 2014-2022,($ MILLIONS)
    • 5.2.2. GLOBAL GASTRIC CANCER MARKET , 2014-2022,($ MILLIONS)
    • 5.2.3. GLOBAL LYMPHOMA MARKET, 2014-2022,($ MILLIONS)
    • 5.2.4. GLOBAL PROSTATE CANCER MARKET, 2014-2022,($ MILLIONS)
    • 5.2.5. GLOBAL NON-SMALL CELL LUNG CARCINOMA MARKET, 2014-2022,($ MILLIONS)
    • 5.2.6. GLOBAL OTHER DISEASE MARKET, 2014-2022,($ MILLIONS)
  • 5.3. GLOBAL TISSUE DIAGNOSTIC MARKET BY PRODUCT, 2014-2022,($ MILLIONS)
    • 5.3.1. GLOBAL INSTRUMENT MARKET, 2014-2022,($ MILLIONS)
    • 5.3.2. GLOBAL CONSUMABLES MARKET, 2014-2022,($ MILLIONS)
  • 5.4. GLOBAL TISSUE DIAGNOSTIC MARKET BY END USER, 2014-2022,($ MILLIONS)
    • 5.4.1. GLOBAL HOSPITALS MARKET, 2014-2022,($ MILLIONS)
    • 5.4.2. GLOBAL PHARMACEUTICALS MARKET, 2014-2022,($ MILLIONS)
    • 5.4.3. GLOBAL RESEARCH LABORATORIES MARKET, 2014-2022,($ MILLIONS)
    • 5.4.4. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET, 2014-2022,($ MILLIONS)
    • 5.4.5. GLOBAL OTHERS MARKET, 2014-2022,($ MILLIONS)

6. COMPETITIVE LANDSCAPE

  • 6.1. MARKET SHARE
  • 6.2. STRATEGY - AN ANALYSIS ACROSS TIERS

7. GEOGRAPHICAL ANALYSIS

  • 7.1. NORTH AMERICA TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
    • 7.1.1. UNITED STATES (U.S.) TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
    • 7.1.2. CANADA TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
  • 7.2. EUROPE TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
    • 7.2.1. UNITED KINGDOM (UK) TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
    • 7.2.2. FRANCE TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
    • 7.2.3. GERMANY TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
    • 7.2.4. SPAIN TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
    • 7.2.5. ITALY TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
    • 7.2.6. ROE TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
  • 7.3. ASIA PACIFIC TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
    • 7.3.1. INDIA TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
    • 7.3.2. CHINA TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
    • 7.3.3. JAPAN TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
    • 7.3.4. KOREA TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
    • 7.3.5. AUSTRALIA TISSUE MONITORING MARKET T, 2014-2022,($MILLIONS)
    • 7.3.6. ROAPAC TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
  • 7.4. REST OF THE WORLD TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
    • 7.4.1. LATIN AMERICA TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
    • 7.4.2. MENA TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)
    • 7.4.3. AFRICA TISSUE MONITORING MARKET, 2014-2022,($MILLIONS)

8. COMPANY PROFILES

  • 1. ROCHE
  • 2. ABBOTT LABORATORIES, INC.
  • 3. AGILENT TECHNOLOGIES
  • 4. BIOGENEX LABORATORIES
  • 5. BIO SB.
  • 6. CELL SIGNALLING TECHNOLOGY, INC.
  • 7. QIAGEN
  • 8. BECTON DICKINSON & COMPANY
  • 9. ALERE
  • 10. DIAGENIC
  • 11. MEDTRONIC INC
  • 12. STRYKER
  • 13. BIOMERIUX
  • 14. PROMETHEUS LABORATORIES
  • 15. DANAHER CORPORATION.

LIST OF TABLES

  • 1. GLOBAL TISSUE DIAGNOSTIC MARKET BY TECHNOLOGY, 2014-2022,($ MILLIONS)
  • 2. GLOBAL IMMUNOHISTOCHEMISTRY MARKET BY PRODUCT, 2014-2022,($ MILLIONS)
  • 3. GLOBAL IN SITU HYBRIDIZATION MARKET, 2014-2022,($ MILLIONS)
  • 4. GLOBAL DIGITAL PATHOLOGY AND WORKFLOW MANAGEMENT MARKET, 2014-2022,($ MILLIONS)
  • 5. GLOBAL MAGNETOENCEPHALOGRAPH MARKET, 2014-2022,($ MILLIONS)
  • 6. GLOBAL SPECIAL STAINING MARKET, 2014-2022,($ MILLIONS)
  • 7. GLOBAL TISSUE DIAGNOSTIC MARKET BY DISEASE, 2014-2022,($ MILLIONS)
  • 8. GLOBAL BREAST CANCER MARKET, 2014-2022,($ MILLIONS)
  • 9. GLOBAL GASTRIC CANCER MARKET , 2014-2022,($ MILLIONS)
  • 10. GLOBAL LYMPHOMA MARKET, 2014-2022,($ MILLIONS)
  • 11. GLOBAL PROSTATE CANCER MARKET, 2014-2022,($ MILLIONS)
  • 12. GLOBAL NON-SMALL CELL LUNG CARCINOMA MARKET, 2014-2022,($ MILLIONS)
  • 13. GLOBAL OTHER DISEASE MARKET, 2014-2022,($ MILLIONS)
  • 14. GLOBAL TISSUE DIAGNOSTIC MARKET BY PRODUCT, 2014-2022,($ MILLIONS)
  • 15. GLOBAL INSTRUMENT MARKET, 2014-2022,($ MILLIONS)
  • 16. GLOBAL CONSUMABLES MARKET, 2014-2022,($ MILLIONS)
  • 17. GLOBAL TISSUE DIAGNOSTIC MARKET BY END USER, 2014-2022,($ MILLIONS)
  • 18. GLOBAL HOSPITALS MARKET, 2014-2022,($ MILLIONS)
  • 19. GLOBAL PHARMACEUTICALS MARKET, 2014-2022,($ MILLIONS)
  • 20. GLOBAL RESEARCH LABORATORIES MARKET, 2014-2022,($ MILLIONS)
  • 21. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET, 2014-2022,($ MILLIONS)
  • 22. GLOBAL OTHERS MARKET, 2014-2022,($ MILLIONS)

LIST OF FIGURES

  • 1. UNITED STATES (U.S.) TISSUE DIAGNOSTIC MARKET, 2014-2022 ($MILLIONS)
  • 2. CANADA TISSUE DIAGNOSTIC MARKET, 2014-2022 ($MILLIONS)
  • 3. UNITED KINGDOM (UK) TISSUE DIAGNOSTIC MARKET, 2014-2022 ($MILLIONS)
  • 4. FRANCE TISSUE DIAGNOSTIC MARKET, 2014-2022 ($MILLIONS)
  • 5. GERMANY TISSUE DIAGNOSTIC MARKET, 2014-2022 ($MILLIONS)
  • 6. SPAIN TISSUE DIAGNOSTIC MARKET, 2014-2022 ($MILLIONS)
  • 7. ITALY TISSUE DIAGNOSTIC MARKET, 2014-2022 ($MILLIONS)
  • 8. ROE TISSUE DIAGNOSTIC MARKET, 2014-2022 ($MILLIONS)
  • 9. INDIA TISSUE DIAGNOSTIC MARKET, 2014-2022 ($MILLIONS)
  • 10. CHINA TISSUE DIAGNOSTIC MARKET, 2014-2022 ($MILLIONS)
  • 11. JAPAN TISSUE DIAGNOSTIC MARKET, 2014-2022 ($MILLIONS)
  • 12. KOREA TISSUE DIAGNOSTIC MARKET, 2014-2022 ($MILLIONS)
  • 13. AUSTRALIA TISSUE DIAGNOSTIC MARKET, 2014-2022 ($MILLIONS)
  • 14. ROAPAC TISSUE DIAGNOSTIC MARKET, 2014-2022 ($MILLIONS)
  • 15. LATIN AMERICA TISSUE DIAGNOSTIC MARKET, 2014-2022 ($MILLIONS)
  • 16. MENA TISSUE DIAGNOSTIC MARKET, 2014-2022 ($MILLIONS)
  • 17. AFRICA TISSUE DIAGNOSTIC MARKET, 2014-2022 ($MILLIONS)
Back to Top